Clinicopathological features of cutaneous reactions after mRNA‐based COVID‐19 vaccines

Tihy, Matthieu; Menzinger, Sébastien; André, R; Laffitte, Emmanuel; Toutous-Trellu, Laurence; Kaya, Gürkan

doi:10.1111/jdv.17633

Cited by 22 publications

(45 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study by Català et al, the ‘COVID arm’ was much more common in females (95.4%) and is more likely to be associated with systemic symptoms (64.6%) than other post-vaccination eruptions [ 2 ]. It can manifest as a solitary pink patch or plaque associated with erythema, induration, pruritus, and/or tenderness ( Figure 1 ) [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. Severe reactions with lesion sizes of >10 cm have been reported [ 9 ].…”

Section: Resultsmentioning

confidence: 99%

“…The former is a potential contraindication to the second dose. One hundred twenty-eight cases of urticarial eruption were reported in 12 studies [ 1 , 2 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ], of which 57 (44.5%) were after BNT162b2, 47 (36.7%) after mRNA-1273, and 24 (18.8%) after AZD1222 vaccination ( Figure 2 ). Of these cases, 11 were labeled by the CDC as part of an anaphylaxis reaction and submitted to the Vaccine Adverse Event Reporting System (VAERS) [ 18 ].…”

Section: Resultsmentioning

confidence: 99%

“…Twelve studies detailed 95 morbilliform/maculopapular eruptions, of which 53 (55.3%) were after BNT162b2, 31 (33.0%) after mRNA-1273, and 11 (11.7%) after AZD1222 vaccination ( Table 1 ; Figure 3 ) [ 1 , 2 , 17 , 18 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. In the AAD/ILDS registry, such eruptions started at a median of 3 days after the first dose and two days after the second dose [ 1 ].…”

Section: Resultsmentioning

confidence: 99%

“…A laboratory investigation showed increased liver enzymes and the second vaccine dose was not provided. Tihy et al indicated that morbilliform eruptions shared histopathologic similarities with drug eruption [ 17 ]. Ohsawa and colleagues demonstrated similarities between the immunohistochemical features of morbilliform eruption in one case and those found in COVID-19-associated skin lesions [ 86 ].…”

Section: Resultsmentioning

confidence: 99%

“…Pityriasis rosea is a complication that appeared within 22 days and resolved within 12 weeks of vaccination [ 1 , 2 , 16 , 17 , 21 , 23 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. It was associated with BNT162b2 vaccination in most patients (71.9%; 41 of 57 eruptions, Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review

Khan

Hussein

Shareef

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background : After introducing Covid‐19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration. Methods : Databases were searched, covering a timeline from December 1, 2019 to February 28, 2022. Data were independently extracted and accessed for bias. SPSS statistical software version 25 was used for appropriate inferential statistics. Results : Thirty‐one studies were included for data extraction after screening following the eligibility criteria. A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea‐like eruptions after vaccination, out of which 36 (55.38%) were female. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose. It was found popularly in the trunk area, either asymptomatically or with mild symptoms. Meantime the onset, was 8.58 days, and meantime it took to recover, was 6.44 weeks. Conclusion : The association between pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease.

show abstract

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Singh

Freeman

2022

Curr Derm Rep

View full text Add to dashboard Cite

Purpose of Review This review aims to evaluate the spectrum of cutaneous reactions after both SARS-CoV-2 infection and COVID-19 vaccination while simultaneously understanding the evolution of the field of dermatology in the face of an ongoing pandemic. Recent Findings The most commonly reported cutaneous reactions after COVID-19 infection in the literature to date include morbilliform or maculopapular rashes, chilblains, and urticaria. The incidence of cutaneous reactions after COVID-19 vaccination was 9% in larger cohort studies and more commonly occurred after mRNA-based COVID-19 vaccines than adenovirus vector vaccines. The most frequently reported cutaneous reactions after COVID-19 vaccines were delayed large local reactions, local injection site reactions, urticarial eruptions, and morbilliform eruptions. Summary With the ongoing pandemic, and continued development of new COVID-19 variants and vaccines, the landscape of cutaneous reactions continues to rapidly evolve. Dermatologists have an important role in evaluating skin manifestations of the virus, as well as discussion and promoting COVID-19 vaccination for their patients.

show abstract

Clinicopathological features of cutaneous reactions after mRNA‐based COVID‐19 vaccines

Cited by 22 publications

References 12 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Contact Info

Product

Resources

About